HealthStream Announces Fourth Quarter & Full-year 2020 Results
HealthStream, a provider of healthcare workforce solutions, reported its financial results for Q4 and the full year 2020. Q4 revenues were $61.8 million, down 1% from $62.7 million in Q4 2019. Operating income decreased by 66% to $1.1 million, influenced by $3.0 million in operating losses from recent acquisitions. Full-year revenues declined to $244.8 million, a 4% decrease, while operating income increased by 7% to $15.8 million. The EPS remained stable at $0.44 per share for both years. For 2021, the company forecasts revenue between $242.5 million and $252.5 million.
- Operational improvements led to an increase in full-year operating income by 7% to $15.8 million.
- Completed five acquisitions in 2020, enhancing workforce solutions and expanding service offerings.
- Achieved a significant milestone with over 4.22 million contracted subscriptions for hStream technology.
- Q4 revenues decreased by 1% YoY, reflecting challenges in legacy product sales.
- Operating income for Q4 fell 66%, primarily due to acquisition-related costs, impacting profitability.
- Full-year revenues declined by 4%, indicating a downward trend in sales performance.
HealthStream, Inc. (Nasdaq: HSTM), a leading provider of workforce and provider solutions for the healthcare industry, announced today results for the fourth quarter and full year ended December 31, 2020. In this earnings release, results are presented for continuing operations only, unless otherwise indicated, as our results for the fourth quarter and full-year 2019 reflect a gain on the sale of our previously divested Patient Experience (PX) business included in discontinued operations.
Fourth Quarter 2020
-
Revenues of
$61.8 million , down1% from$62.7 million in the fourth quarter of 2019 -
Operating income of
$1.1 million , down66% from$3.3 million in the fourth quarter of 2019, which comparison was negatively impacted in the amount of$3.0 million by operating losses associated with the four companies we acquired during 2020 (driven in part by deferred revenue write-downs), along with diligence and other professional expenses associated with such acquisitions -
Income from continuing operations of
$0.9 million , down74% from$3.6 million in the fourth quarter of 2019, which comparison was negatively impacted in the amount of$2.3 million associated with the factors noted above under operating income -
Earnings per share (EPS) from continuing operations of
$0.03 per share (diluted), compared to$0.11 per share (diluted) in the fourth quarter of 2019, which was negatively impacted in the amount of$0.07 associated with the factors noted above under operating income -
Adjusted EBITDA1 from continuing operations of
$10.7 million , down4% from$11.2 million in the fourth quarter of 2019 -
Completed the acquisition of ShiftWizard, Inc., a Raleigh, North Carolina-based company focused on providing a SaaS-based scheduling solution, on October 12, 2020 for approximately
$32.0 million -
Completed the acquisition of Change Healthcare’s staff scheduling business, which includes their ANSOSTM Staff Scheduling application and related products, on December 2, 2020 for approximately
$67.5 million -
Completed the acquisition of myClinicalExchange LLC, a Denver-based information technologies company, on December 10, 2020 for approximately
$4.5 million
Full-Year 2020
-
Revenues of
$244.8 million , down4% from$254.1 million in 2019 -
Operating income of
$15.8 million , up7% from$14.7 million in 2019 -
Income from continuing operations of
$14.1 million , down1% from$14.2 million in 2019 -
Earnings per share (EPS) from continuing operations of
$0.44 per share (diluted) for both 2020 and 2019 -
Adjusted EBITDA from continuing operations of
$46.0 million , down2% from$47.2 million in 2019 -
Authorized a share repurchase program to repurchase up to
$30.0 million of outstanding shares of common stock on March 13, 2020, with shares valued at approximately$20.0 million having been repurchased through the end of 2020.
2021 Event
-
Completed the acquisition of ComplyALIGN, a Chicago-based healthcare technology company, on January 19, 2021, for
$2.0 million in cash
Financial Results:
Fourth Quarter 2020 Compared to Fourth Quarter 2019
Revenues for the fourth quarter of 2020 decreased by
Revenues from our Workforce Solutions segment were
Revenues from our Provider Solutions segment were
Generally accepted accounting principles (GAAP) require companies to write down beginning balances of acquired deferred revenue balances as part of “fair value” accounting as defined by GAAP. During the fourth quarter of 2020 and 2019, HealthStream reported a reduction of
Operating income was
Income from continuing operations was
Adjusted EBITDA from continuing operations was
At December 31, 2020, the Company had cash and cash equivalents and marketable securities of
Full-Year 2020 Compared to Full-Year 2019
For 2020, revenues were
Other Business Updates
At December 31, 2020, we had approximately 4.22 million contracted subscriptions to hStream™, our Platform-as-a-Service technology. hStream technology enables healthcare organizations and their respective workforces to easily connect to and gain value from the growing HealthStream ecosystem of applications, tools, data, and content.
On March 13, 2020, the Company’s Board of Directors authorized a share repurchase program to repurchase up to
On October 12, 2020, the Company acquired ShiftWizard, Inc., a Raleigh, North Carolina-based company focused on providing a SaaS-based solution that integrates key workforce management capabilities, including scheduling, productivity, and forecasting, for approximately
On December 2, 2020, the Company acquired all of the equity interests of Change Healthcare’s staff scheduling business, consisting of the ANSOSTM Staff Scheduling application and related products. The consideration paid for ANSOS consisted of
On December 10, 2020, the Company acquired substantially all of the assets of myClinicalExchange, LLC, a Denver, Colorado-based information technologies company offering a SaaS-based solution that allows healthcare organizations to track, manage, and report the intern and clinical rotation educational requirements of medical, nursing, and allied healthcare students, as well as host required documentation for medical residents. The consideration paid for myClinicalExchange consisted of
First Quarter 2021 Event
On January 19, 2021, the Company acquired the issued and outstanding equity of ProcessDATA, Ltd. (d/b/a ComplyALIGN and HospitalPORTAL), a Chicago-based healthcare technology company, for
Financial Outlook for 2021
The Company is providing guidance for 2021 for the measures set forth below, including adjusted EBITDA, a non-GAAP financial measure as defined later in this release. For a reconciliation of projected adjusted EBITDA to projected net loss (the most comparable GAAP measure) for 2021, see the table included on page 11 of this release.
|
Full Year 2021 Guidance |
||||||||
Revenue |
|
Low |
|
|
High |
|
|
||
Workforce Solutions |
|
$ |
195.0 |
|
- |
$ |
203.0 |
|
million |
Provider Solutions |
|
|
47.5 |
|
- |
|
49.5 |
|
million |
Consolidated |
|
$ |
242.5 |
|
- |
$ |
252.5 |
|
million |
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA1 |
|
$ |
34.0 |
|
- |
$ |
38.3 |
|
million |
|
|
|
|
|
|
|
|
|
|
Capital Expenditures |
|
$ |
25.0 |
|
- |
$ |
27.0 |
|
million |
1. Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of projected adjusted EBITDA to projected net loss (the most comparable GAAP measure) is included later in this release. |
|||||||||
The Company’s guidance for 2021 as set forth above reflects the Company’s assumptions regarding, among other things, the COVID-19 pandemic as noted below, anticipated integration costs and additional investments in sales, marketing, and product development in 2021 for recently acquired companies, and estimated deferred revenue write-downs of
The Company’s financial guidance assumes that public health conditions associated with the pandemic and general economic conditions (including conditions impacting healthcare organizations) continue to improve over the course of the year, including that COVID-19 vaccines are successfully distributed and perform according to current expectations and that new variants of the virus, or other unknown variants, do not further impede recovery from the pandemic.
Robert A. Frist, Jr., Chief Executive Officer, HealthStream, said “In 2020, we launched a new solution suite focused on nurse & staff scheduling that was formed from three acquisitions made during the year: NurseGrid, ShiftWizard, and ANSOS and is being led by Senior Vice President, Scott McQuigg. Another acquisition in December was made, as well as another one in January, both adding to our workforce solutions. In 2020 alone, over 180 new contracts were signed for our American Red Cross resuscitation suite. Subscriptions of our PaaS-enabled hStream platform exceeded four million by the end of the year—and is now led by Senior Vice President, Kevin O’Hara.”
Frist added, “2020 was also a year of great technology innovations for the Company. In the fourth quarter, fifteen Brandon Hall industry awards were bestowed upon HealthStream, recognizing a half-dozen of our products for their innovation and effectiveness in healthcare organizations. HealthStream was also awarded two patents for its innovations in the fourth quarter. This past year has been very busy with many significant developments that position us well for 2021 and thereafter.”
A conference call with Robert A. Frist, Jr., Chief Executive Officer, Scott A. Roberts, Chief Financial Officer and Senior Vice President, and Mollie Condra, Vice President of Investor Relations and Corporate Communications, will be held on Tuesday, February 23, 2021, at 9:00 a.m. (ET). To listen to the conference, please dial 877-647-2842 (no conference ID needed) if you are calling within the domestic U.S. or Canada. If you are an international caller, please dial 914-495-8564 (no conference ID needed). The conference may also be accessed by going to http://ir.healthstream.com/events.cfm for the simultaneous Webcast of the call, which will subsequently be available for replay. The replay telephone numbers are 855-859-2056 (conference ID #4689062) for U.S. and Canadian callers and 404-537-3406 (conference ID #4689062) for international callers.
Use of Non-GAAP Financial Measures
This press release presents adjusted EBITDA from continuing operations and adjusted EBITDA, both of which are non-GAAP financial measures used by management in analyzing the Company’s financial results and ongoing operational performance.
In order to better assess the Company’s financial results, management believes that net income excluding the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses and before interest, income taxes, stock based compensation, depreciation and amortization, changes in fair value of non-marketable equity investments, and the de-recognition of non-cash royalty expense resulting from our resolution of a mutual disagreement related to various elements of a past partnership which resulted in a reduction to cost of sales in the first quarter of 2020 (“adjusted EBITDA”) is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash and non-operating items which may not, in any such case, fully reflect the underlying operating performance of our business. Management also believes that adjusted EBITDA from continuing operations is a useful measure for evaluating the operating performance of the Company because such measure excludes the results of operations of the PX business that we no longer own and the gain on sale in connection with the sale of such business in February 2018 and thus reflects the Company’s ongoing business operations and assists in comparing the Company’s results of operations between periods. We also believe that adjusted EBITDA and adjusted EBITDA from continuing operations are useful to many investors to assess the Company’s ongoing results from current operations.
The Company has revised its definition of adjusted EBITDA and adjusted EBITDA from continuing operations to adjust for the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses, and has made this update for the calculation of such non-GAAP financial measures for all periods presented herein. Following the completion of any acquisition by the Company, the Company must record the acquired deferred revenue at fair value as defined in GAAP, which may result in a write-down of deferred revenue. If the Company is required to record a write-down of deferred revenue, it may result in lower recognized revenue, operating income, and net income in subsequent periods. Revenue for any such acquired business is deferred and is typically recognized over a one-to-two year period following the completion of any particular acquisition, so our GAAP revenues for this one-to-two year period will not reflect the full amount of revenues that would have been reported if the acquired deferred revenue was not written down to fair value. Management believes that including an adjustment in the definition of adjusted EBITDA for the impact of the deferred write-downs associated with fair value accounting for acquired businesses provides useful information to investors because the deferred revenue write-down recognized in periods after an acquisition may, given the nature of this non-cash accounting impact, cause our GAAP financial results during such periods to not fully reflect our underlying operating performance and thus adjusting for this amount may assist in comparing the Company’s results of operations between periods.
Adjusted EBITDA and adjusted EBITDA from continuing operations are non-GAAP financial measures and should not be considered as measures of financial performance under GAAP. Because adjusted EBITDA and adjusted EBITDA from continuing operations are not measurements determined in accordance with GAAP, such non-GAAP financial measures are susceptible to varying calculations. Accordingly, adjusted EBITDA and adjusted EBITDA from continuing operations, as presented, may not be comparable to other similarly titled measures of other companies and have limitations as analytical tools.
These non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance, which are prepared in accordance with GAAP. Investors are encouraged to review the reconciliations of adjusted EBITDA to net income (loss) (the most comparable GAAP measure) and adjusted EBITDA from continuing operations to net income (loss) from continuing operations (the most comparable GAAP measure), which are set forth below in this release.
About HealthStream
HealthStream (Nasdaq: HSTM) is dedicated to improving patient outcomes through the development of healthcare organizations’ greatest asset: their people. Our unified suite of solutions is contracted by healthcare organizations across the U.S. for workforce development, training & learning management, nurse & staff scheduling, clinical education, credentialing, privileging, provider enrollment, performance assessment, and managing simulation-based education programs. HealthStream’s corporate office is in Nashville, Tennessee. For more information, visit http://www.healthstream.com or call 800-521-0574.
HEALTHSTREAM, INC. |
||||||||||||||||
Condensed Consolidated Statements of Income |
||||||||||||||||
(In thousands, except per share data) |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
Three Months Ended December 31, |
Year Ended December 31, |
|
||||||||||||
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||
Revenues, net |
|
$ |
61,818 |
|
|
$ |
62,695 |
|
|
$ |
244,826 |
|
|
$ |
254,112 |
|
Operating costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues (excluding depreciation and amortization) |
|
|
22,736 |
|
|
|
24,875 |
|
|
|
89,332 |
|
|
|
103,890 |
|
Product development |
|
|
8,815 |
|
|
|
7,346 |
|
|
|
32,305 |
|
|
|
29,109 |
|
Sales and marketing |
|
|
9,010 |
|
|
|
9,601 |
|
|
|
35,297 |
|
|
|
37,945 |
|
Other general and administrative expenses |
|
|
11,936 |
|
|
|
10,296 |
|
|
|
41,885 |
|
|
|
40,579 |
|
Depreciation and amortization |
|
|
8,184 |
|
|
|
7,240 |
|
|
|
30,189 |
|
|
|
27,869 |
|
Total operating costs and expenses |
|
|
60,681 |
|
|
|
59,358 |
|
|
|
229,008 |
|
|
|
239,392 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
|
1,137 |
|
|
|
3,337 |
|
|
|
15,818 |
|
|
|
14,720 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (expense) income, net |
|
|
(1 |
) |
|
|
681 |
|
|
|
2,005 |
|
|
|
3,209 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before income tax provision |
|
|
1,136 |
|
|
|
4,018 |
|
|
|
17,823 |
|
|
|
17,929 |
|
Income tax provision |
|
|
213 |
|
|
|
464 |
|
|
|
3,732 |
|
|
|
3,733 |
|
Income from continuing operations |
|
|
923 |
|
|
|
3,554 |
|
|
|
14,091 |
|
|
|
14,196 |
|
Discontinued operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on sale of discontinued operations |
|
|
— |
|
|
|
93 |
|
|
|
— |
|
|
|
2,053 |
|
Income tax (benefit) provision |
|
|
— |
|
|
|
(36 |
) |
|
|
— |
|
|
|
479 |
|
Income from discontinued operations |
|
|
— |
|
|
|
129 |
|
|
|
— |
|
|
|
1,574 |
|
Net income |
|
$ |
923 |
|
|
$ |
3,683 |
|
|
$ |
14,091 |
|
|
$ |
15,770 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share – basic: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
0.03 |
|
|
$ |
0.11 |
|
|
$ |
0.44 |
|
|
$ |
0.44 |
|
Discontinued operations |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.05 |
|
Earnings per share - basic |
|
$ |
0.03 |
|
|
$ |
0.11 |
|
|
$ |
0.44 |
|
|
$ |
0.49 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share - diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
0.03 |
|
|
$ |
0.11 |
|
|
$ |
0.44 |
|
|
$ |
0.44 |
|
Discontinued operations |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.05 |
|
Earnings per share - diluted |
|
$ |
0.03 |
|
|
$ |
0.11 |
|
|
$ |
0.44 |
|
|
$ |
0.49 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares of common stock outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
31,552 |
|
|
|
32,379 |
|
|
|
31,960 |
|
|
|
32,372 |
|
Diluted |
|
|
31,594 |
|
|
|
32,465 |
|
|
|
31,989 |
|
|
|
32,428 |
|
HEALTHSTREAM, INC. |
||||||||
Condensed Consolidated Balance Sheets |
||||||||
(In thousands) |
||||||||
(Unaudited) |
||||||||
|
|
December 31, |
|
|
December 31, |
|
||
|
|
2020 |
|
|
2019 |
|
||
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
36,566 |
|
|
$ |
131,538 |
|
Marketable securities |
|
|
9,928 |
|
|
|
41,328 |
|
Accounts and unbilled receivables, net |
|
|
46,100 |
|
|
|
30,376 |
|
Prepaid and other current assets |
|
|
22,131 |
|
|
|
21,330 |
|
Total current assets |
|
|
114,725 |
|
|
|
224,572 |
|
|
|
|
|
|
|
|
|
|
Capitalized software development, net |
|
|
26,631 |
|
|
|
21,445 |
|
Property and equipment, net |
|
|
22,218 |
|
|
|
26,065 |
|
Operating lease right of use assets, net |
|
|
28,081 |
|
|
|
29,615 |
|
Goodwill and intangible assets, net |
|
|
279,155 |
|
|
|
162,277 |
|
Deferred tax assets |
|
|
974 |
|
|
|
269 |
|
Deferred commissions |
|
|
19,907 |
|
|
|
17,645 |
|
Other assets |
|
|
8,622 |
|
|
|
7,656 |
|
Total assets |
|
$ |
500,313 |
|
|
$ |
489,544 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable, accrued and other liabilities |
|
$ |
38,266 |
|
|
$ |
39,674 |
|
Deferred revenue |
|
|
81,176 |
|
|
|
65,511 |
|
Total current liabilities |
|
|
119,442 |
|
|
|
105,185 |
|
Deferred tax liabilities |
|
|
14,523 |
|
|
|
13,183 |
|
Deferred revenue, non-current |
|
|
1,603 |
|
|
|
1,918 |
|
Operating lease liability, non-current |
|
|
28,479 |
|
|
|
30,733 |
|
Other long-term liabilities |
|
|
2,204 |
|
|
|
357 |
|
Total liabilities |
|
|
166,251 |
|
|
|
151,376 |
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity: |
|
|
|
|
|
|
|
|
Common stock |
|
|
271,784 |
|
|
|
290,021 |
|
Accumulated other comprehensive income |
|
|
1 |
|
|
|
4 |
|
Retained earnings |
|
|
62,277 |
|
|
|
48,143 |
|
Total shareholders’ equity |
|
|
334,062 |
|
|
|
338,168 |
|
Total liabilities and shareholders' equity |
|
$ |
500,313 |
|
|
$ |
489,544 |
|
HEALTHSTREAM, INC. |
||||||||
Condensed Consolidated Statements of Cash Flows |
||||||||
(In thousands) |
||||||||
(Unaudited) |
||||||||
|
|
Year Ended |
|
|||||
|
|
December 31, |
|
|
December 31, |
|
||
|
|
2020 |
|
|
2019 |
|
||
Operating activities: |
|
|
|
|
|
|
|
|
Net income |
|
$ |
14,091 |
|
|
$ |
15,770 |
|
Income from discontinued operations |
|
|
— |
|
|
|
(1,574 |
) |
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
30,189 |
|
|
|
27,869 |
|
Amortization of deferred commissions |
|
|
8,768 |
|
|
|
8,305 |
|
Stock based compensation |
|
|
2,217 |
|
|
|
4,244 |
|
Deferred income taxes |
|
|
4,295 |
|
|
|
2,167 |
|
Provision for doubtful accounts |
|
|
274 |
|
|
|
211 |
|
Gain on equity method investments |
|
|
51 |
|
|
|
(64 |
) |
Non-cash royalty expense |
|
|
(3,440 |
) |
|
|
— |
|
Change in fair value of non-marketable equity investments |
|
|
(1,181 |
) |
|
|
— |
|
Other |
|
|
347 |
|
|
|
(72 |
) |
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts and unbilled receivables |
|
|
(2,992 |
) |
|
|
11,605 |
|
Deferred commissions |
|
|
(11,030 |
) |
|
|
(9,479 |
) |
Prepaid and other assets |
|
|
(700 |
) |
|
|
6,518 |
|
Accounts payable, accrued and other liabilities |
|
|
(3,548 |
) |
|
|
2,077 |
|
Deferred revenue |
|
|
(1,467 |
) |
|
|
(1,920 |
) |
Net cash provided by operating activities |
|
|
35,874 |
|
|
|
65,657 |
|
|
|
|
|
|
|
|
|
|
Investing activities: |
|
|
|
|
|
|
|
|
Business combinations, net of cash acquired |
|
|
(121,342 |
) |
|
|
(27,018 |
) |
Proceeds from sale of discontinued operations, net of tax |
|
|
— |
|
|
|
6,070 |
|
Changes in marketable securities |
|
|
30,992 |
|
|
|
(6,739 |
) |
Proceeds from sale of fixed assets |
|
|
— |
|
|
|
15 |
|
Payments to acquire non-marketable equity investments |
|
|
(1,257 |
) |
|
|
(3,342 |
) |
Purchases of property and equipment |
|
|
(1,988 |
) |
|
|
(21,997 |
) |
Payments associated with capitalized software development |
|
|
(16,815 |
) |
|
|
(14,513 |
) |
Net cash used in investing activities |
|
|
(110,410 |
) |
|
|
(67,524 |
) |
|
|
|
|
|
|
|
|
|
Financing activities: |
|
|
|
|
|
|
|
|
Proceeds from exercise of stock options |
|
|
— |
|
|
|
214 |
|
Taxes paid related to net settlement of equity awards |
|
|
(435 |
) |
|
|
(1,034 |
) |
Payment of earn-out related to prior acquisitions |
|
|
— |
|
|
|
(38 |
) |
Repurchases of common stock |
|
|
(20,019 |
) |
|
|
— |
|
Payment of cash dividends |
|
|
(40 |
) |
|
|
(58 |
) |
Net cash used in financing activities |
|
|
(20,494 |
) |
|
|
(916 |
) |
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
58 |
|
|
|
— |
|
Net decrease in cash and cash equivalents |
|
|
(94,972 |
) |
|
|
(2,783 |
) |
Cash and cash equivalents at beginning of period |
|
|
131,538 |
|
|
|
134,321 |
|
Cash and cash equivalents at end of period |
|
$ |
36,566 |
|
|
$ |
131,538 |
|
Reconciliation of GAAP to Non-GAAP Financial Measures(1) |
||||||||||||||||
Operating Results Summary |
||||||||||||||||
(In thousands) |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
Three Months Ended December 31, |
|
|
Year Ended December 31, |
|
||||||||||
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||
GAAP income from continuing operations |
|
$ |
923 |
|
|
$ |
3,554 |
|
|
$ |
14,091 |
|
|
$ |
14,196 |
|
Deferred revenue write-down |
|
|
919 |
|
|
|
51 |
|
|
|
1,274 |
|
|
|
280 |
|
Interest income |
|
|
(74 |
) |
|
|
(733 |
) |
|
|
(993 |
) |
|
|
(3,272 |
) |
Interest expense |
|
|
19 |
|
|
|
26 |
|
|
|
96 |
|
|
|
102 |
|
Income tax provision |
|
|
213 |
|
|
|
464 |
|
|
|
3,732 |
|
|
|
3,733 |
|
Stock based compensation expense |
|
|
553 |
|
|
|
601 |
|
|
|
2,218 |
|
|
|
4,244 |
|
Depreciation and amortization |
|
|
8,184 |
|
|
|
7,240 |
|
|
|
30,189 |
|
|
|
27,869 |
|
Change in fair value of non-marketable equity investments |
|
|
— |
|
|
|
— |
|
|
|
(1,181 |
) |
|
|
— |
|
Non-cash royalty expense |
|
|
— |
|
|
|
— |
|
|
|
(3,440 |
) |
|
|
— |
|
Adjusted EBITDA from continuing operations |
|
$ |
10,737 |
|
|
$ |
11,203 |
|
|
$ |
45,986 |
|
|
$ |
47,152 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net income |
|
$ |
923 |
|
|
$ |
3,683 |
|
|
$ |
14,091 |
|
|
$ |
15,770 |
|
Deferred revenue write-down |
|
|
919 |
|
|
|
51 |
|
|
|
1,274 |
|
|
|
280 |
|
Interest income |
|
|
(74 |
) |
|
|
(733 |
) |
|
|
(993 |
) |
|
|
(3,272 |
) |
Interest expense |
|
|
19 |
|
|
|
26 |
|
|
|
96 |
|
|
|
102 |
|
Income tax provision |
|
|
213 |
|
|
|
428 |
|
|
|
3,732 |
|
|
|
4,212 |
|
Stock based compensation expense |
|
|
553 |
|
|
|
601 |
|
|
|
2,218 |
|
|
|
4,244 |
|
Depreciation and amortization |
|
|
8,184 |
|
|
|
7,240 |
|
|
|
30,189 |
|
|
|
27,869 |
|
Change in fair value of non-marketable equity investments |
|
|
— |
|
|
|
— |
|
|
|
(1,181 |
) |
|
|
— |
|
Non-cash royalty expense |
|
|
— |
|
|
|
— |
|
|
|
(3,440 |
) |
|
|
— |
|
Adjusted EBITDA |
|
$ |
10,737 |
|
|
$ |
11,296 |
|
|
$ |
45,986 |
|
|
$ |
49,205 |
|
(1) This press release presents adjusted EBITDA and adjusted EBITDA from continuing operations, which are non-GAAP financial measures used by management in analyzing its financial results and ongoing operational performance. |
||||||||||||||||
Reconciliation of GAAP to Non-GAAP Financial Measures |
||||||||
Financial Outlook for 2021 |
||||||||
(In thousands) |
||||||||
(Unaudited) |
||||||||
|
|
Low |
|
|
High |
|
||
Net loss |
|
$ |
(7,200 |
) |
|
$ |
(4,200 |
) |
Deferred revenue write-down |
|
|
5,300 |
|
|
|
4,300 |
|
Interest income |
|
|
(100 |
) |
|
|
(100 |
) |
Interest expense |
|
|
100 |
|
|
|
100 |
|
Income tax benefit |
|
|
(2,500 |
) |
|
|
(1,500 |
) |
Stock based compensation expense |
|
|
2,400 |
|
|
|
2,700 |
|
Depreciation and amortization |
|
|
37,000 |
|
|
|
38,000 |
|
Reversal of PTO accrual |
|
|
(1,000 |
) |
|
|
(1,000 |
) |
Adjusted EBITDA |
|
$ |
34,000 |
|
|
$ |
38,300 |
|
This press release includes certain forward-looking statements (statements other than solely with respect to historical fact), including statements regarding expectations for financial performance for 2021 as well as the anticipated impact of the COVID-19 pandemic on our financial results, that involve risks and uncertainties regarding HealthStream. These statements are based upon management’s beliefs, as well as assumptions made by and data currently available to management. This information has been, or in the future may be, included in reliance on the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by the forward-looking statements, including, without limitation, as the result of developments related to the COVID-19 pandemic, including, without limitation, related to the length and severity of the pandemic; the timing and availability of medical treatments and vaccines with respect to COVID-19; the timing and effectiveness of the ongoing rollout of currently available vaccines; the spread of potentially more contagious and/or virulent forms of the virus; business and economic conditions resulting from the pandemic; the impact on the pandemic on healthcare organizations; measures we are taking to respond to the pandemic; the impact of governmental action and regulation in connection with the pandemic (including the CARES Act); potential workforce disruptions; and the disruption in capital and financial markets; as well as risks referenced in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed on February 26, 2020, the Company’s Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2020, filed on October 29, 2020, and in the Company’s other filings with the Securities and Exchange Commission from time to time. Consequently, such forward-looking information should not be regarded as a representation or warranty or statement by the Company that such projections will be realized. Many of the factors that will determine the Company’s future results are beyond the ability of the Company to control or predict. Readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. The Company undertakes no obligation to update or revise any such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005800/en/
FAQ
What were HealthStream's Q4 2020 revenues?
How did HealthStream's EPS change in Q4 2020?
What were HealthStream's full-year revenues for 2020?
How many acquisitions did HealthStream complete in 2020?
What is HealthStream's revenue guidance for 2021?
